2 months ago
BIIB
AnalystsAndrew TsaiAndrew Tsai's Stock Forecasts
AnalystsAndrew Tsai
Analyst Ranking
Bottom 10%
#4614 out of 5121 analysts
Average Return
-3.15%
Win Rate
42%11 out of 26
Risk vs Reward
Poor
Good
Andrew Tsai's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cerevel Therapeutics Holdings IncCERE | +139.30% | $14.20 | $33.98 | 2020-11-22 - 2021-11-22 | Strong Buy |
Stoke Therapeutics IncSTOK | +125.49% | $13.22 | $29.81 | 2025-07-17 - 2025-12-02 | Strong Buy |
Sarepta Therapeutics IncSRPT | +58.93% | $12.88 | $20.47 | 2025-07-23 - 2025-12-02 | Strong Buy |
Bridgebio Pharma IncBBIO | +49.84% | $47.69 | $71.46 | 2025-07-13 - 2025-12-02 | Strong Buy |
Axsome Therapeutics IncAXSM | +44.25% | $98.50 | $142.09 | 2025-04-06 - 2025-12-02 | Strong Buy |
Andrew Tsai Analyst Color
Get additional color on Andrew Tsai's coverage of popular stocks
a year ago
SRPT
Andrew Tsai's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Maplight Therapeutics IncMPLT | 1 | Strong Buy | $32.00 | +148.25% | Initiates Coverage On | 12 days ago |
Alto Neuroscience IncANRO | 2 | Strong Buy | $25.00 | +95.31% | Maintains | 21 days ago |
Avadel Pharmaceuticals PLCAVDL | 1 | Hold | $20.00 | -6.32% | Downgrades | a month ago |
Praxis Precision Medicines IncPRAX | 1 | Strong Buy | $300.00 | +67.49% | Maintains | 2 months ago |
Akero Therapeutics IncAKRO | 1 | Hold | $56.00 | +2.77% | Downgrades | 2 months ago |
Biogen IncBIIB | 1 | Strong Buy | $190.00 | +5.45% | Initiates Coverage On | 2 months ago |
Sarepta Therapeutics IncSRPT | 3 | Strong Buy | $35.00 | +70.98% | Maintains | 4 months ago |
Stoke Therapeutics IncSTOK | 1 | Strong Buy | $30.00 | +0.64% | Initiates Coverage On | 5 months ago |
Bridgebio Pharma IncBBIO | 1 | Strong Buy | $70.00 | -2.04% | Initiates Coverage On | 5 months ago |
Verona Pharma PLCVRNA | 1 | Strong Buy | $110.00 | +2.89% | Maintains | 6 months ago |
Rocket Pharmaceuticals IncRCKT | 2 | Hold | $2.50 | -19.09% | Downgrades | 6 months ago |
Axsome Therapeutics IncAXSM | 1 | Strong Buy | $200.00 | +40.76% | Initiates Coverage On | 8 months ago |
Ke Holdings IncBEKE | 2 | Strong Buy | $27.00 | +61.39% | Maintains | 8 months ago |
Marinus Pharmaceuticals IncMRNS | 1 | Hold | $0.50 | N/A | Downgrades | a year ago |
Relmada Therapeutics IncRLMD | 2 | Strong Buy | $13.00 | N/A | Upgrades | a year ago |
Rapport Therapeutics IncRAPP | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | a year ago |
Fusion Pharmaceuticals IncFUSN | 1 | Hold | $21.00 | N/A | Downgrades | 2 years ago |
Vistagen Therapeutics IncVTGN | 2 | Strong Buy | $15.00 | N/A | Upgrades | 2 years ago |
Lexicon Pharmaceuticals IncLXRX | 1 | Hold | $3.00 | N/A | Initiates Coverage On | 3 years ago |
Athira Pharma IncATHA | 2 | Hold | $30.00 | N/A | Downgrades | 3 years ago |
Vigil Neuroscience IncVIGL | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 4 years ago |
Intra Cellular Therapies IncITCI | 1 | Strong Buy | $70.00 | N/A | Maintains | 4 years ago |
Atai Beckley NvATAI | 1 | Strong Buy | $27.00 | N/A | Initiates Coverage On | 4 years ago |
Cerevel Therapeutics Holdings IncCERE | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 5 years ago |
Xenon Pharmaceuticals IncXENE | 1 | Strong Buy | $23.00 | N/A | Assumes | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.